Fundraising Fox

Alafair Biosciences

Austin, US · Founded 2011 · Delaware corporation · 3 known investors

Alafair Biosciences develops advanced bioresorbable biomaterials for surgical soft tissue healing and motion preservation. The company serves surgeons and patients undergoing procedures requiring post-surgical recovery, with a focus on preventing tissue tethering and supporting natural mobility.

BiotechDeep TechMedical DevicesNew Materials

Founders & leadership

Alafair Biosciences was founded in 2011 by Sarah Mayes.

SM
Sarah MayesChief Scientific Officer and Co-founder
DP
Daniel PetersonExecutive
JJJohn Joyoprayitno
John JoyoprayitnoinPresident and Chief Executive Officer

Board

JD
Jerry DeVriesinBoard directorManaging Partner at TEXO Ventures
RW
Robert WillsBoard director
CL
Christophe LavigneBoard director
JB
John B. Henneman, IIIBoard director
JP
James P. FellerBoard director

Investors · 3

ATPAustin
TEXO VenturesAustin
UT Horizon FundAustin

Reported raises · per SEC filings

Form D private placements

$6M disclosed across 5 rounds · 2011–2018

▶$2.3MraisedOct 2018 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Daniel PetersonDirector
  • Jerry DeVriesDirector
  • Mark BenedykDirector
  • James Patrick FellerDirector
  • Kyle A. CoxDirector
  • John B. HennemanDirector
  • John JoyoprayitnoExecutive Officer
  • R. Gregory BrophyExecutive Officer
Offering amount
$6.8M
Amount sold
$2.3M
First sale
Sep 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$965KraisedJul 2017 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Daniel PetersonDirector
  • John B. HennemanDirector
  • R. Gregory BrophyExecutive Officer
  • John JoyoprayitnoExecutive Officer
  • James Patrick FellerDirector
  • Jerry DeVriesDirector
  • Kyle A. CoxDirector
  • Jim GamettDirector
Offering amount
$2M
Amount sold
$965K
First sale
Jun 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$984KraisedOct 2015 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert WillsDirector
  • Daniel PetersonExecutive Officer, Director
  • Jerry DeVriesDirector
  • Christophe LavigneDirector
  • John B. Henneman, IIIDirector
  • James P. FellerDirector
  • John JoyoprayitnoExecutive Officer
Offering amount
$2M
Amount sold
$984K
First sale
Oct 2015
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedMay 2014 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Christophe LavigneDirector
  • Robert WillsDirector
  • John JoyoprayitnoExecutive Officer
  • Jerry DeVriesDirector
  • Daniel PetersonExecutive Officer, Director
  • James P. FellerDirector
Offering amount
$2M
Amount sold
$1M
First sale
Apr 2014
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$702KraisedJan 2012 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James P. FellerDirector
  • Daniel PetersonExecutive Officer, Director
  • John JoyoprayitnoExecutive Officer
  • Jerry DeVriesDirector
Offering amount
$1.5M
Amount sold
$702K
First sale
Nov 2011
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Aro Biotherapeutics11 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.

Companies competing with Alafair Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Alafair Biosciences do?
Alafair Biosciences develops advanced bioresorbable biomaterials for surgical soft tissue healing and motion preservation. The company serves surgeons and patients undergoing procedures requiring post-surgical recovery, with a focus on preventing tissue tethering and supporting natural mobility.
Who founded Alafair Biosciences?
Alafair Biosciences was founded by Sarah Mayes in 2011.
Who are Alafair Biosciences's investors?
Alafair Biosciences's investors include ATP, TEXO Ventures, UT Horizon Fund.
How much funding has Alafair Biosciences raised?
Alafair Biosciences has disclosed $6M raised across 5 rounds.
Where is Alafair Biosciences headquartered?
Alafair Biosciences is headquartered in Austin, US.